Jameel Health & LPIXEL Announce Strategic Collaboration to Enhance Medical Image Diagnosis Using AI Technology in MENAT and Global South Regions.

Dubai, UAE – Jameel Health, through Abdul Latif Jameel General Trading Co., Japan, is excited to announce a strategic collaboration with LPIXEL Inc. to distribute LPIXEL’s next-generation AI medical imaging diagnostic support technology, EIRL, across selected MENAT and Global South markets.

The EIRL series by LPIXEL heralds a new era in AI-driven medical diagnostics, offering an accurate, efficient, and streamlined solution to support clinicians in interpreting medical images amidst the increasing demand for diagnostic imaging. The lineup, consisting of six products covering radiology (X-ray, CT, and MRI) and real-time colonoscopy, supports diagnostics across multiple medical specialties, including neurology, pulmonology, and gastroenterology. Products like EIRL Chest Screening⁵ and EIRL  Brain Aneurysm help prevent the oversight of lung nodules and cerebral aneurysms, potentially improving clinical outcomes for patients.

Since its establishment in 2014, LPIXEL has emerged as a pioneer in AI image analysis. EIRL products have earned the trust of clinicians across Japan, performing over 6.4 million analyses in more than 800 medical institutions¹.

This strategic collaboration aims to provide clinicians in the MENAT region with powerful diagnostic tools to enhance the quality of medical care and improve patient outcomes through the early detection of diseases using AI technology.

Jameel Health, through Abdul Latif Jameel General Trading Co., Japan, aims to widely promote LPIXEL’s technology as a medical diagnostic support tool through unique alliances with universities and hospitals across the Middle East. Initially, the exclusive distribution will focus on KSA and UAE, with plans for extended distribution in selected MENAT and Global South regions.

---

¹ Cumulatively, as of May 2024. Trials included.

² EIRL Aneurysm – Approval no: 30100BZX00142000

³ EIRL Brain Metry – Certification no: 230AGBZX00107Z00

⁴ EIRL Brain Segmentation – Certification no: 303AGBZX00043Z00

⁵ Chest Screening is a package containing the following products:

   EIRL Chest XR – Approval number: 30400BZX00285000, EIRL Chest Metry – Certification number: 302AGBZX00101000

⁶ EIRL Chest CT – Certification no: 304AGBZX00037Z00

⁷ EIRL Colon Polyp – Approval number: 30400BZX00259000

Notes to Editors

About Jameel Health

Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.

Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges.  Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow.  It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.

Abdul Latif Jameel actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.

Abdul Latif Jameel Copyright Notice and Disclaimer

© Meddist Company Ltd. (Jameel Health).  All rights fully reserved.  The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.

The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.

This document may contain forward-looking statements.  Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Jameel Health or Abdul Latif Jameel entities or their respective managements.  Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases.  However, the absence of such words does not mean that a particular statement is not forward looking.  Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Jameel Health or Abdul Latif Jameel entities.  Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements.  Further, any forward-looking statement speaks only as of the date on which it is made, and neither Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.  All forward-looking statements made by Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.

No Offer or Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

About LPIXEL Inc

(LPIXEL Inc. headquartered in Otemachi, Chiyoda-ku, Tokyo, Japan)

Established in 2014, LPIXEL is a leading provider of artificial intelligence-based image analysis technologies within the medical and life science industries.

Dedicated to improving the lives of clinicians and the health of patients, LPIXEL’s flagship series of Software as a Medical Device (SaMD) products, ‘EIRL’, assists clinicians with the interpretation of medical images including radiological scans (X-ray, CT, MRI) and colonoscopy, and has performed over 4.9 million analyses to date.⁴

In addition to clinical products, LPIXEL also accelerates R&D across the life sciences by delivering bespoke image analysis solutions to leading pharmaceutical and medical device companies with a focus on addressing challenges across all stages of the drug development pipeline, from drug discovery to clinical trials.

For more information, please visit https://lpixel.net/en/

About Abdul Latif Jameel General Trading Co. Ltd.

(headquartered in Chiyoda-ku, Tokyo, President and Representative Director: Shigeki ENAMI)

Established in 1996 as HOBI Co. Ltd., an affiliated office of Abdul Latif Jameel Company Ltd, the business focused on exports of vehicles manufactured by the Toyota Group to the Middle East. Today, as Abdul Latif Jameel General Trading Co. Ltd., we introduce Japanese companies and their products and services worldwide, while maintaining our core businesses centered on the Middle East and Asia. Learn more: alj-japan.co.jp or contact us here: alj-japan.co.jp/english/contact/